Tested lab-chosen drug combo for recurrent brain tumor
Part of Cancer clinical trials.
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 21 or older, and you can do most daily activities (ECOG 0 to 2).
- Your life expectancy is more than 3 months, and you can take standard treatment that includes temozolomide and radiation when your diagnosis is confirmed.
- Your brain tumor is high-grade astrocytic glioma proven by pathology, and you’ve already had surgery/biopsy plus temozolomide and radiation.
- Your tumor has progressed after first treatment, and your doctor thinks it’s appropriate to try another (second-line) systemic therapy.
- Enough tumor tissue is available to run the lab test (and at least one lab result is available or pending).
- Your blood counts, liver, kidneys, and swallowing ability are adequate to safely take the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
Hear when a new Glioma, Astrocytic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.